JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The company plans to submit the IND application by the end of 2021
In his previous assignment Perfetti was associated with Fabbrica Italiana Sintetici (F.I.S) as Chief Commercial Officer
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Subscribe To Our Newsletter & Stay Updated
